In a world where AI is evolving rapidly, one question keeps coming up in healthcare, especially in evidence generation and market access: “Can an AI chatbot replace a systematic literature review (SLR)?” As the founder of Oncoscope-AI, a platform focused on transforming how we track and synthesize oncology evidence, my answer is simple: No — not even close.
But there’s a much more important follow-up: AI can fundamentally transform how SLRs are built, maintained, and used — if we apply it the right way.
Why SLRs Are Still the Gold Standard
Systematic literature reviews are foundational tools in evidence-based medicine. They are methodologically rigorous, reproducible, and transparent — all critical features when informing high-stakes decisions in drug development, health technology assessments (HTAs), clinical guidelines, and reimbursement.
A well-conducted SLR isn’t just a literature search. It’s a structured, protocol-driven process governed by frameworks like PRISMA, Cochrane, or GRADE. It includes clear inclusion/exclusion criteria, detailed documentation of search strategies, dual reviewer consensus, and often a meta-analysis.
In short: SLRs build trust — because the process is as important as the outcome.
Where AI Chatbots Fall Short
While chatbots like ChatGPT, OpenEvidence, Perplexity, or other LLM-based tools can sound authoritative and answer questions quickly, they have significant limitations when it comes to replacing SLRs.
- No audit trail: Chatbots can’t show exactly where their answers came from.
- No methodological transparency: There’s no documentation of inclusion/exclusion criteria or search strategies.
- No reproducibility: Two people asking the same question may get different answers.
- Risk of hallucinations: These tools may confidently return incorrect or fabricated information.
These characteristics make them fundamentally incompatible with the standards required in clinical research, regulatory decision-making, or payer engagement.
What AI Can Do for Evidence Synthesis
While chatbots can’t replace SLRs, AI can absolutely enhance the way SLRs are performed, maintained, and consumed. This is the space we are focused on at Oncoscope-AI.
Here’s how:
1. Real-Time Monitoring of New Evidence
AI can continuously scan new publications, clinical trial databases, regulatory announcements, and guideline updates — surfacing relevant changes in near real-time.
2. Efficient Screening and Categorization
AI can rapidly identify and classify articles based on criteria defined in a protocol, dramatically reducing the manual burden on human reviewers. At Oncoscope, we trained and validated AI programs to deliver over 99% accuracy for this task – with details on rejections well beyond what humans are used to provide.
3. Smarter Data Extraction
While AI can’t yet extract all types of data reliably, there are many variables where it already performs as well as — or even better than — humans. At Oncoscope, we carefully evaluate each type of data we need to extract, and we implement AI selectively and responsibly. The rule of thumb we follow is: if you can standardize it, you can automate it. Structured variables can often be automated — freeing our experts to focus on the more complex and nuanced interpretation.
4. Version Control and Living Updates
Traditional SLRs are static snapshots. At Oncoscope, we’re enabling “Living SLRs” — always current, always linked to their sources, and always grounded in rigorous methods.
5. Actionable Summaries Without Compromising Rigor
Using AI for extraction and summarization doesn’t mean cutting corners. It means scaling expertise, speeding updates, and freeing time for deeper interpretation.
Our Vision at Oncoscope-AI
We are not building another chatbot. We are building an evidence engine that understands how oncology evolves — one that stays current without sacrificing standards.
Our platform continuously tracks:
- Peer-reviewed publications
- Major oncology conference abstracts
- Trial registrations at ct.gov
- Clinical guidelines (currently all relevant USA guidelines, adding EU soon)
- Regulatory approvals (FDA, and adding EMA)
All of this is structured, sourced, and updated in real time — providing oncologists and other healthcare professionals with a living map of the oncology evidence landscape.
In short, we’re bringing the structure of an SLR and the speed of AI together — without compromising either.
Final Thoughts
So, can an AI chatbot replace a systematic literature review?
No — and it shouldn’t.
But AI, when designed for evidence integrity and real-world utility, can transform what an SLR can become. This transformation is no longer hypothetical. It’s happening now — and we’re proud to be leading it at Oncoscope-AI.
Interested in how a Living SLR can support your work in oncology or market access? Let’s connect.
📩 info@oncoscope-ai.com | LinkedIn
Anna Forsythe is the Founder and President of Oncoscope-AI, the first platform to bring together real-time oncology treatment data, clinical guidelines, research publications, and regulatory approvals — all in one place, just like Expedia for cancer care. Available free to oncology professionals worldwide, Oncoscope-AI is redefining how cancer care information is accessed and applied.
A clinically trained Doctor of Pharmacy (PharmD), Anna also holds a Master’s in Health Economics and Policy from the University of Birmingham (UK) and an MBA from Columbia University. She previously co-founded Purple Squirrel Economics (acquired by Cytel in 2020) and led Global Value and Access at Eisai Pharmaceuticals, following earlier roles at Novartis and Bayer in clinical research and health economics.
